Key result
PCSK9 antibodies reduce LDL-C and cardiovascular risk in statin-intolerant or inadequately controlled patients.
Answers are grounded in this paper and cite their sources.
Over the past quarter century, clinical trials have consistently demonstrated that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces the rate of major adverse cardiovascular events. However, the findings that many patients continue to experience events or harbour inappropriately high LDL-C levels despite intensive statin therapy and the clinical reality of statin intolerance suggests that additional therapeutic strategies are required in order to achieve more effective reductions in cardiovascular risk. The emergence of inhibitory monoclonal antibodies targeted against proprotein convertase subtilisin kexin type 9 (PCSK9) provides a novel approach to reducing LDL-C levels. The current experience of PCSK9 inhibitors and implications for clinical use and cost effectiveness will be reviewed.
No takes yet. Share an insight, caveat, or question.
Scherer et al. (2017) conducted a review in Elevated low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. PCSK9 inhibitors was evaluated. PCSK9 inhibitory monoclonal antibodies provide a novel therapeutic approach to reducing LDL-C levels and cardiovascular risk in patients with statin intolerance or inadequately controlled LDL-C.
Synapse has enriched 10 related papers. Consider them for comparative context: